Skip to main content

Table 1 First-line treatment decisions

From: Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

n, % EGFR Mut+
n = 334
EGFR Mut-
n = 2481
EGFR Mx
n = 131
Total
N = 2946
Agent
 Carboplatin 74 (22.2) 1203 (48.5) 62 (47.3) 1339 (45.5)
 Cisplatin 60 (18.0) 897 (36.2) 43 (32.8) 1000 (33.9)
 Pemetrexed 39 (11.7) 754 (30.4) 38 (29.0) 831 (28.2)
 Gemcitabine 37 (11.1) 603 (24.3) 36 (27.5) 676 (22.9)
 Vinorelbine 43 (12.9) 586 (23.6) 41 (31.3) 670 (22.7)
 Paclitaxel 21 (6.3) 284 (11.4) 8 (6.1) 313 (10.6)
 Gefitinib 177 (53.0) 6 (0.2) 0 183 (6.2)
 Bevacizumab 18 (5.4) 142 (5.7) 1 (0.8) 161 (5.5)
 Docetaxel 3 (0.9) 97 (3.9) 1 (0.8) 101 (3.4)
 Etoposide 1 (0.3) 76 (3.1) 3 (2.3) 80 (2.7)
 Erlotinib 12 (3.6) 46 (1.9) 3 (2.3) 61 (2.1)
 Other 0 19 (0.8) 1 (0.8) 20 (0.7)
 Cetuximab 0 3 (0.1) 0 3 (0.1)
Type of treatment
 Combination chemotherapy 117 (35.0) 1947 (78.5) 103 (78.6) 2167 (73.6)
 Monochemotherapya 10 (3.0) 319 (12.9) 23 (17.6) 352 (11.9)
 TKI 189 (56.6) 49 (2.0) 3 (2.3) 241 (8.2)
 Chemotherapy + bevacizumab and/or cetuximab 18 (5.4) 141 (5.7) 1 (0.8) 160 (5.4)
 Not classifiableb 0 19 (0.8) 1 (0.8) 20 (0.7)
 Other 0 6 (0.2) 0 6 (0.2)
  1. Patients with at least one specification of chemotherapy – multiple answers were permitted. Individual agents and treatment type ranked in order of decreasing use in the total population. Mut+, mutation-positive; Mut-, mutation-negative; Mx, mutation unknown/non-evaluable; TKI, tyrosine kinase inhibitor. aCarboplatin, cisplatin, docetaxel, etoposide, gemcitabine, paclitaxel, pemetrexed, vinorelbine. bTherapy schemes included ‘other’ substances (from free text entries)
\